All In MedTech

Device Trial Radar · NCT07113223

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms: a Pragmatic Randomized Clinical Trial (DECISION)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,968 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,968

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Mar 2027

Study completion May 2027

Sponsor

Lead sponsor
Idoven 1903 S.L.Not on our public-company list
Sponsor type
Industry
Collaborators
Hospital Universitario 12 de Octubre; Fundación para la Investigación Biomédica del Hospital Gregorio Maranon; Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria de la Comunidad de Madrid (FIIBAP); Instituto de Investigación Marqués de Valdecilla; Karolinska Institutet; Region Stockholm; AstraZeneca; Servicio Madrileno De Salud (SERMAS)
First posted
Aug 8, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk. This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.

Conditions

  • Heart Failure
  • Cardiovascular Risk Factors

Interventions

  • Willem™ platform ECG assessmentDevice

    AI-assisted ECG analysis via the Willem™ platform

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device performance in patients with suspected Heart FailureTime frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Primary Care: Gerencia Asistencial Atención Primaria Madrid

    Madrid, Spain · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.